Long-acting HIV injectable study for subtype A6
Part of Immune system & allergy, Infections clinical trials.
This study looks back at medical records of people with HIV-1 who have received a long-acting injectable treatment called cabotegravir plus rilpivirine. It aims to see how well this treatment works for people with a specific HIV subtype (A6).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HIV-1.
- You are 18 years or older.
- You have received at least one dose of the long-acting injectable HIV treatment called cabotegravir plus rilpivirine (CAB/RPV LA).
- You agree to let researchers review your medical records for this study.
- You are willing to give a blood sample to check your HIV subtype, if it is not already known.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
This study looks at people in Belgium who have already received at least one dose of a long-acting injectable HIV medication called cabotegravir/rilpivirine. The goal is to learn more about how this treatment works in real-world settings.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
Hear when a new Human Immunodeficiency Virus (HIV)-1 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.